{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:11:47Z","timestamp":1788498707141,"version":"build-2803163510"},"reference-count":219,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40265-025-02223-8","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T17:10:30Z","timestamp":1757956230000},"page":"1207-1230","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Update on Medical Treatment of Cushing\u2019s Syndrome"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2004-3887","authenticated-orcid":false,"given":"Brendan R.","family":"Dillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-9236","authenticated-orcid":false,"given":"Nidhi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5025-0150","authenticated-orcid":false,"given":"Yair","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-1866","authenticated-orcid":false,"given":"Kristen","family":"Dancel-Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1231-3306","authenticated-orcid":false,"given":"Antoine","family":"Tabarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4137-3025","authenticated-orcid":false,"given":"Andr\u00e9","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4897-2197","authenticated-orcid":false,"given":"Leo J.","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-391X","authenticated-orcid":false,"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,15]]},"reference":[{"issue":"7","key":"2223_CR1","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BMK, Colao A. Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol. 2016;4(7):611\u201329.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2223_CR2","volume":"11","author":"LK Nieman","year":"2025","unstructured":"Nieman LK, Castinetti F, Newell-Price J, Valassi E, Drouin J, Takahashi Y, et al. Cushing syndrome. Nat Rev Dis Prim. 2025;11(1):4.","journal-title":"Nat Rev Dis Prim"},{"issue":"Suppl 1","key":"2223_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000314297","volume":"92","author":"C Steffensen","year":"2010","unstructured":"Steffensen C, Bak AM, Z\u00f8ylner Rubeck K, J\u00f8rgensen JOL. Epidemiology of cushing\u2019s syndrome. Neuroendocrinology. 2010;92(Suppl 1):1\u20135.","journal-title":"Neuroendocrinology"},{"issue":"3","key":"2223_CR4","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1210\/clinem\/dgz136","volume":"105","author":"G Rubinstein","year":"2020","unstructured":"Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, et al. Time to diagnosis in Cushing\u2019s syndrome: a meta-analysis based on 5367 patients. J Clin Endocrinol Metab. 2020;105(3):e12-22.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2223_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101521","volume":"35","author":"OA Hakami","year":"2021","unstructured":"Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101521.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2223_CR6","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00648","volume":"11","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, et al. Medical treatment of Cushing\u2019s disease: an overview of the current and recent clinical trials. Front Endocrinol (Lausanne). 2020;11:648.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2223_CR7","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO, et al. Treatment of Cushing\u2019s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807\u201331.","journal-title":"J Clin Endocrinol Metab"},{"key":"2223_CR8","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1060884","volume":"13","author":"A Gilis-Januszewska","year":"2022","unstructured":"Gilis-Januszewska A, Bogus\u0142awska A, Rzepka E, Ziaja W, Hubalewska-Dydejczyk A. Individualized medical treatment options in Cushing disease. Front Endocrinol (Lausanne). 2022;13:1060884.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2223_CR9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9(12):847\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2223_CR10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","volume":"7","author":"RA Feelders","year":"2019","unstructured":"Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A. Advances in the medical treatment of Cushing\u2019s syndrome. Lancet Diabetes Endocrinol. 2019;7(4):300\u201312.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2223_CR11","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1165681","volume":"14","author":"RA Feelders","year":"2023","unstructured":"Feelders RA, Fleseriu M, Kadioglu P, Bex M, Gonz\u00e1lez-Devia D, Boguszewski CL, et al. Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease. Front Endocrinol (Lausanne). 2023;14:1165681.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2223_CR12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","volume":"10","author":"C De Bruin","year":"2009","unstructured":"De Bruin C, Feelders RA, Lamberts SWJ, Hofland LJ. Somatostatin and dopamine receptors as targets for medical treatment of Cushing\u2019s syndrome. Rev Endocr Metab Disord. 2009;10(2):91\u2013102.","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"2223_CR13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med. 2012;366(10):914\u201324.","journal-title":"N Engl J Med"},{"issue":"3","key":"2223_CR14","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","volume":"81","author":"R Pivonello","year":"2014","unstructured":"Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a phase III study. Clin Endocrinol (Oxf). 2014;81(3):408\u201317.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2223_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","volume":"57","author":"S Petersenn","year":"2017","unstructured":"Petersenn S, Salgado LR, Schopohl J, Portocarrero-Ortiz L, Arnaldi G, Lacroix A, et al. Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a phase III trial. Endocrine. 2017;57(1):156\u201365.","journal-title":"Endocrine"},{"issue":"1","key":"2223_CR16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W, Pivonello R, Yu Y, Witek P, et al. Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol. 2018;6(1):17\u201326.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2223_CR17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/cen.14081","volume":"91","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Petersenn S, Biller BMK, Kadioglu P, De Block C, T\u2019Sjoen G, et al. Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a phase III extension study. Clin Endocrinol (Oxf). 2019;91(6):776\u201385.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2223_CR18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12020-015-0557-2","volume":"50","author":"C Simeoli","year":"2015","unstructured":"Simeoli C, Auriemma RS, Tortora F, De Leo M, Iacuaniello D, Cozzolino A, et al. The treatment with pasireotide in Cushing\u2019s disease: effects of long-term treatment on tumor mass in the experience of a single center. Endocrine. 2015;50(3):725\u201340.","journal-title":"Endocrine"},{"key":"2223_CR19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00436","volume":"10","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Iweha C, Salgado L, Mazzuco TL, Campigotto F, Maamari R, et al. Safety and efficacy of subcutaneous pasireotide in patients with Cushing\u2019s disease: results from an open-label, multicenter, single-arm, multinational, expanded-access study. Front Endocrinol (Lausanne). 2019;10:436.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2223_CR20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11102-013-0483-3","volume":"17","author":"A Colao","year":"2014","unstructured":"Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF. Managing hyperglycemia in patients with Cushing\u2019s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17(2):180\u20136.","journal-title":"Pituitary"},{"issue":"6","key":"2223_CR21","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P, et al. Managing pasireotide-associated hyperglycemia: a randomized, open-label, phase IV study. Pituitary. 2021;24(6):887\u2013903.","journal-title":"Pituitary"},{"issue":"7","key":"2223_CR22","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s40618-021-01661-x","volume":"45","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Pivonello C, Simeoli C, De Martino MC, Colao A. The dopaminergic control of Cushing\u2019s syndrome. J Endocrinol Investig. 2022;45(7):1297\u2013315.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"2223_CR23","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, et al. The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2223_CR24","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4158\/EP10031.OR","volume":"16","author":"AR Lila","year":"2010","unstructured":"Lila AR, Gopal RA, Acharya SV, George J, Sarathi V, Bandgar T, et al. Efficacy of cabergoline in uncured (persistent or recurrent) Cushing disease after pituitary surgical treatment with or without radiotherapy. Endocr Pract. 2010;16(6):968\u201376.","journal-title":"Endocr Pract"},{"issue":"2","key":"2223_CR25","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura e Silva L, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary. 2010;13(2):123\u20139.","journal-title":"Pituitary"},{"issue":"5","key":"2223_CR26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur J Endocrinol. 2010;163(5):709\u201316.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2223_CR27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","volume":"17","author":"M Barbot","year":"2014","unstructured":"Barbot M, Albiger N, Ceccato F, Zilio M, Frigo AC, Denaro L, et al. Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary. 2014;17(2):109\u201317.","journal-title":"Pituitary"},{"issue":"1","key":"2223_CR28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-15-0807","volume":"174","author":"P Burman","year":"2016","unstructured":"Burman P, Ed\u00e9n-Engstr\u00f6m B, Ekman B, Karlsson FA, Schwarcz E, Wahlberg J. Limited value of cabergoline in Cushing\u2019s disease: a prospective study of a 6-week treatment in 20 patients. Eur J Endocrinol. 2016;174(1):17\u201324.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2223_CR29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/EJE-16-0662","volume":"176","author":"A Ferriere","year":"2017","unstructured":"Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O, et al. Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study. Eur J Endocrinol. 2017;176(3):305\u201314.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2223_CR30","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40618-018-0936-7","volume":"41","author":"R Palui","year":"2018","unstructured":"Palui R, Sahoo J, Kamalanathan S, Kar SS, Selvarajan S, Durgia H. Effect of cabergoline monotherapy in Cushing\u2019s disease: an individual participant data meta-analysis. J Endocrinol Investig. 2018;41(12):1445\u201355.","journal-title":"J Endocrinol Investig"},{"issue":"12","key":"2223_CR31","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s40618-018-0936-7","volume":"41","author":"R Palui","year":"2018","unstructured":"Palui R, Sahoo J, Kamalanathan S, Kar SS, Selvarajan S, Durgia H, et al. Effect of cabergoline monotherapy in Cushing\u2019s disease: an individual participant data meta-analysis. J Endocrinol Investig. 2018;41(12):1445\u201355. https:\/\/doi.org\/10.1007\/s40618-018-0936-7.","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"2223_CR32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ecl.2014.10.007","volume":"44","author":"RS Auriemma","year":"2015","unstructured":"Auriemma RS, Pivonello R, Ferreri L, Priscitelli P, Colao A. Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015;44(1):89\u201397.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"2223_CR33","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z, et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab. 2019;104(7):2527\u201334.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2223_CR34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s11102-023-01342-3","volume":"26","author":"C Sulu","year":"2023","unstructured":"Sulu C, Gul N, Tanrikulu S, Ciftci S, Yener Ozturk F, Sarac B, et al. Risk of impulse control disorders in patients with Cushing\u2019s disease: do not blame cabergoline but do not give up caution. Pituitary. 2023;26(4):495\u2013509.","journal-title":"Pituitary"},{"issue":"8","key":"2223_CR35","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13118","volume":"34","author":"R Hamblin","year":"2022","unstructured":"Hamblin R, Coulden A, Fountas A, Karavitaki N. The diagnosis and management of Cushing\u2019s syndrome in pregnancy. J Neuroendocrinol. 2022;34(8):e13118.","journal-title":"J Neuroendocrinol"},{"issue":"6","key":"2223_CR36","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","volume":"76","author":"G Raverot","year":"2012","unstructured":"Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, et al. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf). 2012;76(6):769\u201375.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2223_CR37","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, Mccormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1-24.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2223_CR38","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","volume":"108","author":"P Burman","year":"2023","unstructured":"Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM. Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. J Clin Endocrinol Metab. 2023;108(7):1585\u2013601.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2223_CR39","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1210\/clinem\/dgz211","volume":"105","author":"U Elbelt","year":"2020","unstructured":"Elbelt U, Schlaffer SM, Buchfelder M, Knappe UJ, Vila G, Micko A, et al. Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas\u2014a German survey. J Clin Endocrinol Metab. 2020;105(3):e660\u201375.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2223_CR40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","volume":"187","author":"P Burman","year":"2022","unstructured":"Burman P, Trouillas J, Losa M, Mccormack A, Petersenn S, Popovic V, et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol. 2022;187(4):593\u2013605.","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2223_CR41","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","volume":"352","author":"ME Hegi","year":"2005","unstructured":"Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, De Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997\u20131003.","journal-title":"N Engl J Med"},{"key":"2223_CR42","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00290","volume":"10","author":"BM Hauser","year":"2019","unstructured":"Hauser BM, Lau A, Gupta S, Bi WL, Dunn IF. The epigenomics of pituitary adenoma. Front Endocrinol (Lausanne). 2019;10:290.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2223_CR43","volume":"11","author":"C Dai","year":"2020","unstructured":"Dai C, Liang S, Sun B, Kang J. The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas. Front Endocrinol (Lausanne). 2020;11:608422.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"03","key":"2223_CR44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J De Filette","year":"2019","unstructured":"De Filette J, Andreescu C, Cools F, Bravenboer B, Velkeniers B. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res. 2019;51(03):145\u201356.","journal-title":"Horm Metab Res"},{"issue":"10","key":"2223_CR45","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","volume":"103","author":"AL Lin","year":"2018","unstructured":"Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, et al. Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab. 2018;103(10):3925\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2223_CR46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/CAD.0000000000000856","volume":"31","author":"M Caccese","year":"2020","unstructured":"Caccese M, Barbot M, Ceccato F, Padovan M, Gardiman MP, Fassan M, et al. Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anticancer Drugs. 2020;31(2):199\u2013204.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"2223_CR47","first-page":"e239","volume":"6","author":"Y Yang","year":"2020","unstructured":"Yang Y, Hecht JR, Liu ST, Cohen MJ, Hart SD, Wang HL, et al. Caution advised using combination ketoconazole and PD-1 inhibitors. AACE Clin Case Rep. 2020;6(5):e239\u201342.","journal-title":"AACE Clin Case Rep."},{"issue":"2","key":"2223_CR48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001532","volume":"8","author":"N Majd","year":"2020","unstructured":"Majd N, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, et al. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. J Immunother Cancer. 2020;8(2):e001532.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"2223_CR49","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10030088","volume":"10","author":"C Duhamel","year":"2020","unstructured":"Duhamel C, Ilie MD, Salle H, Nassouri AS, Gaillard S, Deluche E, et al. Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature. J Pers Med. 2020;10(3):88.","journal-title":"J Pers Med"},{"issue":"1","key":"2223_CR50","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-20-0151","volume":"184","author":"B Sol","year":"2021","unstructured":"Sol B, De Filette JMK, Awada G, Raeymaeckers S, Aspeslagh S, Andreescu CE, et al. Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment? Eur J Endocrinol. 2021;184(1):K1-5.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2223_CR51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1530\/EJE-22-0647","volume":"187","author":"MD Ilie","year":"2022","unstructured":"Ilie MD, Villa C, Cuny T, Cortet C, Assie G, Baussart B, et al. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Eur J Endocrinol. 2022;187(5):685\u201396.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2223_CR52","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1227\/neu.0000000000002024","volume":"91","author":"S Shah","year":"2022","unstructured":"Shah S, Manzoor S, Rothman Y, Hagen M, Pater L, Golnik K, et al. Complete response of a patient with a mismatch repair deficient aggressive pituitary adenoma to immune checkpoint inhibitor therapy: a case report. Neurosurgery. 2022;91(2):e51\u20136.","journal-title":"Neurosurgery"},{"issue":"1","key":"2223_CR53","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-20-0352","volume":"183","author":"J Newell-Price","year":"2020","unstructured":"Newell-Price J, Nieman LK, Reincke M, Tabarin A. Endocrinology in the time of COVID-19: management of Cushing\u2019s syndrome. Eur J Endocrinol. 2020;183(1):G1-7.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2223_CR54","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","volume":"106","author":"F Castinetti","year":"2021","unstructured":"Castinetti F, Nieman LK, Reincke M, Newell-Price J. Approach to the patient treated with steroidogenesis inhibitors. J Clin Endocrinol Metab. 2021;106(7):2114\u201323.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2223_CR55","doi-asserted-by":"crossref","first-page":"R259","DOI":"10.1530\/EJE-17-1058","volume":"178","author":"T Brue","year":"2018","unstructured":"Brue T, Amodru V, Castinetti F. MANAGEMENT OF ENDOCRINE DISEASE: management of Cushing\u2019s syndrome during pregnancy: solved and unsolved questions. Eur J Endocrinol. 2018;178(6):R259\u201366.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2223_CR56","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A. The treatment of Cushing\u2019s disease. Endocr Rev. 2015;36(4):385\u2013486.","journal-title":"Endocr Rev"},{"issue":"5","key":"2223_CR57","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2265.1987.tb01189.x","volume":"27","author":"DR McCance","year":"1987","unstructured":"McCance DR, Hadden DR, Kennedy L, Sheridan B, Atkinson AB. Clinical experience with ketoconazole as a therapy for patients with Cushing\u2019s syndrome. Clin Endocrinol (Oxf). 1987;27(5):593\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2223_CR58","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, et al. Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab. 2014;99(5):1623\u201330.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2223_CR59","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","volume":"21","author":"LHA Broersen","year":"2018","unstructured":"Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM. Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis. Pituitary. 2018;21(6):631\u201341.","journal-title":"Pituitary"},{"issue":"5","key":"2223_CR60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1530\/EJE-17-0886","volume":"178","author":"J Young","year":"2018","unstructured":"Young J, Bertherat J, Vantyghem MC, Chabre O, Senoussi S, Chadarevian R, et al. Hepatic safety of ketoconazole in Cushing\u2019s syndrome: results of a compassionate use programme in France. Eur J Endocrinol. 2018;178(5):447\u201358.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2223_CR61","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","volume":"7","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Pivonello R, Elenkova A, Salvatori R, Auchus RJ, Feelders RA, et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol. 2019;7(11):855\u201365.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2223_CR62","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","volume":"25","author":"R Pivonello","year":"2022","unstructured":"Pivonello R, Zacharieva S, Elenkova A, T\u00f3th M, Shimon I, Stigliano A, et al. Levoketoconazole in the treatment of patients with endogenous Cushing\u2019s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS). Pituitary. 2022;25(6):911\u201326.","journal-title":"Pituitary"},{"issue":"3","key":"2223_CR63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF03348268","volume":"3","author":"M Sch\u00f6nesh\u00f6fer","year":"1980","unstructured":"Sch\u00f6nesh\u00f6fer M, Schefzig B, Arabin S. Short-term kinetics of serum adrenal steroids and plasma ACTH after a single dose of metyrapone in man. J Endocrinol Investig. 1980;3(3):229\u201336.","journal-title":"J Endocrinol Investig"},{"issue":"11","key":"2223_CR64","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","volume":"100","author":"E Daniel","year":"2015","unstructured":"Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, et al. Effectiveness of metyrapone in treating Cushing\u2019s syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab. 2015;100(11):4146\u201354.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2223_CR65","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","volume":"62","author":"F Ceccato","year":"2018","unstructured":"Ceccato F, Zilio M, Barbot M, Albiger N, Antonelli G, Plebani M, et al. Metyrapone treatment in Cushing\u2019s syndrome: a real-life study. Endocrine. 2018;62(3):701\u201311.","journal-title":"Endocrine"},{"issue":"2","key":"2223_CR66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","volume":"35","author":"JA Verhelst","year":"1991","unstructured":"Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing\u2019s syndrome. Clin Endocrinol (Oxf). 1991;35(2):169\u201378.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2223_CR67","doi-asserted-by":"crossref","first-page":"R263","DOI":"10.1530\/EJE-14-1014","volume":"172","author":"E Daniel","year":"2015","unstructured":"Daniel E, Newell-Price JD. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing\u2019s syndrome. Eur J Endocrinol. 2015;172(6):R263\u201380.","journal-title":"Eur J Endocrinol"},{"issue":"Pt 5","key":"2223_CR68","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1258\/acb.2011.011014","volume":"48","author":"PJ Monaghan","year":"2011","unstructured":"Monaghan PJ, Owen LJ, Trainer PJ, Brabant G, Keevil BG, Darby D. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11\u03b2-hydroxylase inhibitor metyrapone. Ann Clin Biochem. 2011;48(Pt 5):441\u20136.","journal-title":"Ann Clin Biochem"},{"issue":"8","key":"2223_CR69","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1210\/jc.2019-00217","volume":"104","author":"SG Creemers","year":"2019","unstructured":"Creemers SG, Feelders RA, De Jong FH, Franssen GJH, De Rijke YB, Van Koetsveld PM, et al. Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study. J Clin Endocrinol Metab. 2019;104(8):3437\u201349.","journal-title":"J Clin Endocrinol Metab"},{"key":"2223_CR70","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.2147\/DDDT.S315359","volume":"17","author":"M Perosevic","year":"2023","unstructured":"Perosevic M, Tritos NA. Clinical utility of osilodrostat in Cushing\u2019s disease: review of currently available literature. Drug Des Devel Ther. 2023;17:1303\u201312.","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"2223_CR71","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al. Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020;8(9):748\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2223_CR72","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","volume":"107","author":"M Gadelha","year":"2022","unstructured":"Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, et al. Randomized trial of osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab. 2022;107(7):e2882\u201395.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2223_CR73","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","volume":"187","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Newell-Price J, Pivonello R, Shimatsu A, Auchus RJ, Scaroni C, et al. Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension. Eur J Endocrinol. 2022;187(4):531\u201341.","journal-title":"Eur J Endocrinol"},{"key":"2223_CR74","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1236465","volume":"14","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Snyder PJ, Witek P, Bex M, Belaya Z, Turcu AF, et al. Long-term efficacy and safety of osilodrostat in patients with Cushing\u2019s disease: results from the LINC 4 study extension. Front Endocrinol (Lausanne). 2023;14:1236465.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2223_CR75","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","volume":"108","author":"A Dormoy","year":"2023","unstructured":"Dormoy A, Haissaguerre M, Vitellius G, Do Cao C, Geslot A, Drui D, et al. Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: a real-world multicenter study in France. J Clin Endocrinol Metab. 2023;108(6):1475\u201387.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2223_CR76","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1530\/EJE-21-1008","volume":"186","author":"A Tabarin","year":"2022","unstructured":"Tabarin A, Haissaguerre M, Lassole H, Jannin A, Paepegaey AC, Chabre O, et al. Efficacy and tolerance of osilodrostat in patients with Cushing\u2019s syndrome due to adrenocortical carcinomas. Eur J Endocrinol. 2022;186(2):K1-4.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2223_CR77","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-22-0208","volume":"187","author":"F Bonnet-Serrano","year":"2022","unstructured":"Bonnet-Serrano F, Poirier J, Vaczlavik A, Laguillier-Morizot C, Blanchet B, Baron S, et al. Differences in the spectrum of steroidogenic enzyme inhibition between osilodrostat and metyrapone in ACTH-dependent Cushing syndrome patients. Eur J Endocrinol. 2022;187(2):315\u201322.","journal-title":"Eur J Endocrinol"},{"key":"2223_CR78","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.903545","author":"M Detomas","year":"2022","unstructured":"Detomas M, Altieri B, Deutschbein T, Fassnacht M, Dischinger U. Metyrapone versus osilodrostat in the short-term therapy of endogenous Cushing\u2019s syndrome: results from a single center cohort study. Front Endocrinol (Lausanne). 2022. https:\/\/doi.org\/10.3389\/fendo.2022.903545.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2223_CR79","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/cen.14551","volume":"98","author":"F Castinetti","year":"2023","unstructured":"Castinetti F, Amodru V, Brue T. Osilodrostat in Cushing\u2019s disease: the risk of delayed adrenal insufficiency should be carefully monitored. Clin Endocrinol (Oxf). 2023;98(4):629\u201330.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2223_CR80","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1093\/ejendo\/lvad167","volume":"190","author":"A Ferriere","year":"2024","unstructured":"Ferriere A, Salenave S, Puerto M, Young J, Tabarin A. Prolonged adrenal insufficiency following discontinuation of osilodrostat treatment for intense hypercortisolism. Eur J Endocrinol. 2024;190(1):L1-3.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2223_CR81","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1093\/ejendo\/lvad060","volume":"188","author":"J Poirier","year":"2023","unstructured":"Poirier J, Bonnet-Serrano F, Thomeret L, Bouys L, Bertherat J. Prolonged adrenocortical blockade following discontinuation of osilodrostat. Eur J Endocrinol. 2023;188(6):K29-32.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2223_CR82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/js.2018-00269","volume":"3","author":"TB Carroll","year":"2019","unstructured":"Carroll TB, Peppard WJ, Herrmann DJ, Javorsky BR, Wang TS, Patel H, et al. Continuous etomidate infusion for the management of severe Cushing syndrome: validation of a standard protocol. J Endocr Soc. 2019;3(1):1\u201312.","journal-title":"J Endocr Soc"},{"issue":"2","key":"2223_CR83","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0274","volume":"167","author":"VA Preda","year":"2012","unstructured":"Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review. Eur J Endocrinol. 2012;167(2):137\u201343.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2223_CR84","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1530\/EJE-20-0380","volume":"183","author":"SM Constantinescu","year":"2020","unstructured":"Constantinescu SM, Driessens N, Lefebvre A, Furnica RM, Corvilain B, Maiter D. Etomidate infusion at low doses is an effective and safe treatment for severe Cushing\u2019s syndrome outside intensive care. Eur J Endocrinol. 2020;183(2):161\u20137.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2223_CR85","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-12-0358","volume":"167","author":"C Baudry","year":"2012","unstructured":"Baudry C, Coste J, Bou Khalil R, Silvera S, Guignat L, Guibourdenche J, et al. Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center. Eur J Endocrinol. 2012;167(4):473\u201381.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2223_CR86","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1210\/jc.2009-1317","volume":"95","author":"B Donadille","year":"2010","unstructured":"Donadille B, Groussin L, Waintrop C, Abbas H, Tenenbaum F, Dugu\u00e9 MA, et al. Management of Cushing\u2019s syndrome due to ectopic adrenocorticotropin secretion with 1,ortho-1, para\u2019-dichloro-diphenyl-dichloro-ethane: findings in 23 patients from a single center. J Clin Endocrinol Metab. 2010;95(2):537\u201344.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2223_CR87","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/j.1460-2075.1984.tb01879.x","volume":"3","author":"S Bourgeois","year":"1984","unstructured":"Bourgeois S, Pfahl M, Baulieu EE. DNA binding properties of glucocorticosteroid receptors bound to the steroid antagonist RU-486. EMBO J. 1984;3(4):751\u20135.","journal-title":"EMBO J"},{"issue":"2","key":"2223_CR88","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0022-4731(87)90083-5","volume":"26","author":"O Heikinheimo","year":"1987","unstructured":"Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, L\u00e4hteenm\u00e4ki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem. 1987;26(2):279\u201384.","journal-title":"J Steroid Biochem"},{"issue":"2","key":"2223_CR89","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4158\/EP12149.RA","volume":"19","author":"M Fleseriu","year":"2013","unstructured":"Fleseriu M, Molitch ME, Gross C, Schteingart DE, Vaughan TB 3rd, Biller BM. A new therapeutic approach in the medical treatment of Cushing\u2019s syndrome: glucocorticoid receptor blockade with mifepristone. Endocr Pract. 2013;19(2):313\u201326.","journal-title":"Endocr Pract"},{"key":"2223_CR90","unstructured":"Korlym (mifepristone) [package insert]. Menlo Park, CA: Corcept Therapeutics Incorporated; 2019."},{"issue":"3","key":"2223_CR91","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1210\/jcem-61-3-536","volume":"61","author":"LK Nieman","year":"1985","unstructured":"Nieman LK, Chrousos GP, Kellner C, Spitz IM, Nisula BC, Cutler GB, et al. Successful treatment of Cushing\u2019s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab. 1985;61(3):536\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2223_CR92","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40842-020-00105-4","volume":"6","author":"DR Brown","year":"2020","unstructured":"Brown DR, East HE, Eilerman BS, Gordon MB, King EE, Knecht LA, et al. Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations. Clin Diabetes Endocrinol. 2020;6(1):18.","journal-title":"Clin Diabetes Endocrinol"},{"issue":"6","key":"2223_CR93","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BMK, Findling JW, Molitch ME, Schteingart DE, Gross C, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2012;97(6):2039\u201349.","journal-title":"J Clin Endocrinol Metab"},{"key":"2223_CR94","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-015-0059-5","volume":"15","author":"HG Fein","year":"2015","unstructured":"Fein HG, Vaughan TB 3rd, Kushner H, Cram D, Nguyen D. Sustained weight loss in patients treated with mifepristone for Cushing\u2019s syndrome: a follow-up analysis of the SEISMIC study and long-term extension. BMC Endocr Disord. 2015;15:63.","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"2223_CR95","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101381","volume":"34","author":"A Ferriere","year":"2020","unstructured":"Ferriere A, Tabarin A. Cushing\u2019s syndrome: treatment and new therapeutic approaches. Best Pract Res Clin Endocrinol Metab. 2020;34(2):101381.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2223_CR96","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/modpathol.2008.19","volume":"21","author":"GL Mutter","year":"2008","unstructured":"Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21(5):591\u20138.","journal-title":"Mod Pathol"},{"issue":"4","key":"2223_CR97","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.contraception.2018.05.020","volume":"98","author":"C Berger","year":"2018","unstructured":"Berger C, Boggavarapu N, Norlin E, Queckb\u00f6rner S, H\u00f6rnaeus K, Falk A, et al. Molecular characterization of PRM-associated endometrial changes, PAEC, following mifepristone treatment. Contraception. 2018;98(4):317\u201322.","journal-title":"Contraception"},{"key":"2223_CR98","volume":"12","author":"R Pivonello","year":"2021","unstructured":"Pivonello R, Bancos I, Feelders RA, Kargi AY, Kerr JM, Gordon MB, et al. Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study. Front Endocrinol (Lausanne). 2021;12:662865.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2223_CR99","volume":"256","author":"EM Viho","year":"2022","unstructured":"Viho EM, Kroon J, Feelders RA, Houtman R, Van Den Dungen E, Pereira Arias AM, et al. Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition. J Endocrinol Investig. 2022;256(2):e220263.","journal-title":"J Endocrinol Investig"},{"issue":"Suppl 1","key":"2223_CR100","doi-asserted-by":"crossref","first-page":"SUN-451","DOI":"10.1210\/js.2019-SUN-451","volume":"3","author":"R Auchus","year":"2019","unstructured":"Auchus R, Findling J, Moraitis A. SUN-451 a randomized-withdrawal, placebo-controlled, phase 3 study to assess the efficacy and safety of selective glucocorticoid receptor antagonist, relacorilant, in patients with Cushing syndrome (GRACE study). J Endocr Soc. 2019;3(Suppl 1):SUN-451.","journal-title":"J Endocr Soc."},{"issue":"Suppl 1","key":"2223_CR101","first-page":"A671","volume":"8","author":"R Pivonello","year":"2024","unstructured":"Pivonello R, Arnaldi G, Auchus RJ, Badiu CP, Cannavo S, Dischinger U, et al. 9323 open-label results from GRACE, a phase 3 double-blind, randomized-withdrawal study of the selective glucocorticoid receptor modulator relacorilant for the treatment of endogenous hypercortisolism (Cushing syndrome). J Endocr Soc. 2024;8(Suppl 1):A671\u20132.","journal-title":"J Endocr Soc."},{"issue":"Suppl","key":"2223_CR102","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2024.09.027","volume":"278","author":"R Pivonello","year":"2024","unstructured":"Pivonello R, Arnaldi G, Auchus RJ, Badiu C, Busch RS, Cannavo S, et al. Medical treatment of hypercortisolism with relacorilant: final results of the phase 3 GRACE study. Am Heart J. 2024;278(suppl):10\u201311.","journal-title":"Am Heart J"},{"issue":"1","key":"2223_CR103","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.eprac.2023.09.011","volume":"30","author":"DM Donegan","year":"2024","unstructured":"Donegan DM, Pivonello R, Stigliano A, Lardo P, Kearney T, Mez\u0151si E, et al. Relacorilant, a selective glucocorticoid receptor modulator in development for the treatment of patients with Cushing syndrome, does not cause prolongation of the cardiac QT interval. Endocr Pract. 2024;30(1):11\u20138.","journal-title":"Endocr Pract"},{"issue":"5463","key":"2223_CR104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","volume":"288","author":"M Rocheville","year":"2000","unstructured":"Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288(5463):154\u20137.","journal-title":"Science"},{"issue":"19","key":"2223_CR105","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA, De Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med. 2010;362(19):1846\u20138.","journal-title":"N Engl J Med"},{"issue":"10","key":"2223_CR106","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0030-1253419","volume":"118","author":"H Bode","year":"2010","unstructured":"Bode H, Seiz M, Lammert A, Brockmann MA, Back W, Hammes HP, et al. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes. 2010;118(10):760\u20133.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"2223_CR107","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11060-014-1702-0","volume":"122","author":"F Ceccato","year":"2015","unstructured":"Ceccato F, Lombardi G, Manara R, Emanuelli E, Denaro L, Milanese L, et al. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. J Neurooncol. 2015;122(1):189\u201396.","journal-title":"J Neurooncol"},{"issue":"9996","key":"2223_CR108","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing\u2019s syndrome. Lancet. 2015;386(9996):913\u201327.","journal-title":"Lancet"},{"issue":"10418","key":"2223_CR109","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1016\/S0140-6736(23)01961-X","volume":"402","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Gatto F, Wildemberg LE, Fleseriu M. Cushing\u2019s syndrome. Lancet. 2023;402(10418):2237\u201352.","journal-title":"Lancet"},{"issue":"9","key":"2223_CR110","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenicky","year":"2011","unstructured":"Kamenicky P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2011;96(9):2796\u2013804.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2223_CR111","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1507\/endocrj.EJ19-0617","volume":"67","author":"T Tanaka","year":"2020","unstructured":"Tanaka T, Satoh F, Ujihara M, Midorikawa S, Kaneko T, Takeda T, et al. A multicenter, phase 2 study to evaluate the efficacy and safety of osilodrostat, a new 11\u03b2-hydroxylase inhibitor, in Japanese patients with endogenous Cushing\u2019s syndrome other than Cushing\u2019s disease. Endocr J. 2020;67(8):841\u201352.","journal-title":"Endocr J"},{"key":"2223_CR112","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/DHPS.S453105","volume":"16","author":"M Stasiak","year":"2024","unstructured":"Stasiak M, Witek P, Adamska-Fita E, Lewinski A. Response to osilodrostat therapy in adrenal Cushing\u2019s syndrome. Drug Healthc Patient Saf. 2024;16:35\u201342.","journal-title":"Drug Healthc Patient Saf"},{"issue":"6","key":"2223_CR113","first-page":"267","volume":"8","author":"RB Malik","year":"2022","unstructured":"Malik RB, Ben-Shlomo A. Adrenal cushing\u2019s syndrome treated with preoperative osilodrostat and adrenalectomy. AACE Clin Case Rep. 2022;8(6):267\u201370.","journal-title":"AACE Clin Case Rep"},{"issue":"4","key":"2223_CR114","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-46.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2223_CR115","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476\u201390.","journal-title":"Ann Oncol"},{"issue":"2","key":"2223_CR116","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282\u2013326.","journal-title":"Endocr Rev"},{"issue":"1","key":"2223_CR117","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1210\/jc.2012-2851","volume":"98","author":"V Chortis","year":"2013","unstructured":"Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O\u2019Neil DM, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5alpha-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98(1):161\u201371.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2223_CR118","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2265.1987.tb01171.x","volume":"27","author":"BG Robinson","year":"1987","unstructured":"Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR, et al. The effect of o,p\u2019-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf). 1987;27(4):437\u201344.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2223_CR119","first-page":"526","volume":"124","author":"AP van Seters","year":"1991","unstructured":"van Seters AP, Moolenaar AJ. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh). 1991;124(5):526\u201333.","journal-title":"Acta Endocrinol (Copenh)."},{"issue":"4","key":"2223_CR120","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1530\/EJE-14-0913","volume":"172","author":"JB Corcuff","year":"2015","unstructured":"Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol. 2015;172(4):473\u201381.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2223_CR121","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","volume":"160","author":"F Castinetti","year":"2009","unstructured":"Castinetti F, Fassnacht M, Johanssen S, Terzolo M, Bouchard P, Chanson P, et al. Merits and pitfalls of mifepristone in Cushing\u2019s syndrome. Eur J Endocrinol. 2009;160(6):1003\u201310.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2223_CR122","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1210\/js.2018-00261","volume":"3","author":"A Kyrilli","year":"2019","unstructured":"Kyrilli A, Lytrivi M, Bouquegneau MS, Demetter P, Lucidi V, Garcia C, et al. Unilateral adrenalectomy could be a valid option for primary nodular adrenal disease: evidence from twins. J Endocr Soc. 2019;3(1):129\u201334.","journal-title":"J Endocr Soc"},{"issue":"2","key":"2223_CR123","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PAS.0000000000000748","volume":"41","author":"KM Lowe","year":"2017","unstructured":"Lowe KM, Young WF Jr, Lyssikatos C, Stratakis CA, Carney JA. Cushing syndrome in Carney complex: clinical, pathologic, and molecular genetic findings in the 17 affected Mayo Clinic patients. Am J Surg Pathol. 2017;41(2):171\u201381.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2223_CR124","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/MED.0000000000000538","volume":"27","author":"M Maillet","year":"2020","unstructured":"Maillet M, Bourdeau I, Lacroix A. Update on primary micronodular bilateral adrenocortical diseases. Curr Opin Endocrinol Diabetes Obes. 2020;27(3):132\u20139.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"2223_CR125","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1515\/jpem-2018-0413","volume":"32","author":"SS Memon","year":"2019","unstructured":"Memon SS, Thakkar K, Patil V, Jadhav S, Lila AR, Fernandes G, et al. Primary pigmented nodular adrenocortical disease (PPNAD): single centre experience. J Pediatr Endocrinol Metab. 2019;32(4):391\u20137.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2223_CR126","doi-asserted-by":"publisher","DOI":"10.1159\/000540691","author":"D Corica","year":"2024","unstructured":"Corica D, Lugara C, Bertherat J, Pasmant E, Valenzise M, Pepe G, et al. Adrenal Cushing syndrome: diagnosis and management in a 10-year-old boy with Carney complex. Horm Res Paediatr. 2024. https:\/\/doi.org\/10.1159\/000540691.","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2223_CR127","doi-asserted-by":"crossref","first-page":"300","DOI":"10.14310\/horm.2002.1514","volume":"14","author":"MR Campo","year":"2015","unstructured":"Campo MR, Lamacchia O, Farese A, Conserva A, Picca G, Grilli G, et al. Mitotane and Carney complex: ten years follow-up of a low-dose mitotane regimen inducing a sustained correction of hypercortisolism. Hormones (Athens). 2015;14(2):300\u20134.","journal-title":"Hormones (Athens)"},{"issue":"3","key":"2223_CR128","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12020-021-02645-w","volume":"71","author":"L Bouys","year":"2021","unstructured":"Bouys L, Chiodini I, Arlt W, Reincke M, Bertherat J. Update on primary bilateral macronodular adrenal hyperplasia (PBMAH). Endocrine. 2021;71(3):595\u2013603.","journal-title":"Endocrine"},{"issue":"4","key":"2223_CR129","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1210\/endrev\/bnac034","volume":"44","author":"J Bertherat","year":"2023","unstructured":"Bertherat J, Bourdeau I, Bouys L, Chasseloup F, Kamenicky P, Lacroix A. Clinical, pathophysiologic, genetic, and therapeutic progress in primary bilateral macronodular adrenal hyperplasia. Endocr Rev. 2023;44(4):567\u2013628.","journal-title":"Endocr Rev"},{"issue":"2","key":"2223_CR130","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-16-0467","volume":"175","author":"M Fassnacht","year":"2016","unstructured":"Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175(2):G1-34.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2223_CR131","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1210\/clinem\/dgab512","volume":"106","author":"I Bancos","year":"2021","unstructured":"Bancos I, Prete A. Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab. 2021;106(11):3331\u201353.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2223_CR132","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.7326\/M20-7946","volume":"174","author":"A Kjellbom","year":"2021","unstructured":"Kjellbom A, Lindgren O, Puvaneswaralingam S, Londahl M, Olsen H. Association between mortality and levels of autonomous cortisol secretion by adrenal incidentalomas: a cohort study. Ann Intern Med. 2021;174(8):1041\u20139.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2223_CR133","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2213-8587(13)70211-0","volume":"2","author":"G Di Dalmazi","year":"2014","unstructured":"Di Dalmazi G, Vicennati V, Garelli S, Casadio E, Rinaldi E, Giampalma E, et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing\u2019s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2(5):396\u2013405.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2223_CR134","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1210\/jc.2014-3007","volume":"99","author":"M Debono","year":"2014","unstructured":"Debono M, Bradburn M, Bull M, Harrison B, Ross RJ, Newell-Price J. Cortisol as a marker for increased mortality in patients with incidental adrenocortical adenomas. J Clin Endocrinol Metab. 2014;99(12):4462\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2223_CR135","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/M21-1737","volume":"175","author":"A Prete","year":"2022","unstructured":"Prete A, Subramanian A, Bancos I, Chortis V, Tsagarakis S, Lang K, et al. Cardiometabolic disease burden and steroid excretion in benign adrenal tumors: a cross-sectional multicenter study. Ann Intern Med. 2022;175(3):325\u201334.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2223_CR136","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7326\/M18-3630","volume":"171","author":"YS Elhassan","year":"2019","unstructured":"Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, et al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis. Ann Intern Med. 2019;171(2):107\u201316.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2223_CR137","first-page":"254","volume":"70","author":"V de Miguel","year":"2010","unstructured":"de Miguel V, Redal MA, Viale ML, Kahan M, Glerean M, Beskow A, et al. Aberrant expression of glucagon receptors in adrenal glands of a patient with Cushing\u2019s syndrome and ACTH-independent macronodular adrenal hyperplasia. Medicina (B Aires). 2010;70(3):254\u20136.","journal-title":"Medicina (B Aires)."},{"issue":"11","key":"2223_CR138","volume":"11","author":"K Shah","year":"2019","unstructured":"Shah K, Mann I, Reddy K, John G. A case of severe psychosis due to Cushing\u2019s syndrome secondary to primary bilateral macronodular adrenal hyperplasia. Cureus. 2019;11(11):e6162.","journal-title":"Cureus"},{"key":"2223_CR139","volume":"2014","author":"S Comte-Perret","year":"2014","unstructured":"Comte-Perret S, Zanchi A, Gomez F. Long-term low-dose ketoconazole treatment in bilateral macronodular adrenal hyperplasia. Endocrinol Diabetes Metab Case Rep. 2014;2014:140083.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"6","key":"2223_CR140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1507\/endocrj.48.665","volume":"48","author":"N Omori","year":"2001","unstructured":"Omori N, Nomura K, Omori K, Takano K, Obara T. Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH). Endocr J. 2001;48(6):665\u20139.","journal-title":"Endocr J"},{"issue":"1","key":"2223_CR141","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s12020-011-9549-z","volume":"41","author":"M Yoshida","year":"2012","unstructured":"Yoshida M, Umeda H, Iwama S, Nakayama S, Miyata M, Ogawa K, et al. Assessment of long-term efficacy and safety of metyrapone monotherapy in a patient with ACTH-independent macronodular adrenal hyperplasia. Endocrine. 2012;41(1):160\u20131.","journal-title":"Endocrine"},{"key":"2223_CR142","first-page":"21","volume":"2021","author":"V Amodru","year":"2021","unstructured":"Amodru V, Brue T, Castinetti F. Synergistic cortisol suppression by ketoconazole-osilodrostat combination therapy. Endocrinol Diabetes Metab Case Rep. 2021;2021:21\u20130071.","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"9","key":"2223_CR143","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1210\/jc.2017-00823","volume":"102","author":"M Debono","year":"2017","unstructured":"Debono M, Harrison RF, Chadarevian R, Gueroult C, Abitbol JL, Newell-Price J. Resetting the abnormal circadian cortisol rhythm in adrenal incidentaloma patients with mild autonomous cortisol secretion. J Clin Endocrinol Metab. 2017;102(9):3461\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"2223_CR144","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.2169\/internalmedicine.50.5578","volume":"50","author":"Y Obata","year":"2011","unstructured":"Obata Y, Yamada Y, Baden MY, Hosokawa Y, Saisho K, Tamba S, et al. Long-term efficacy of trilostane for Cushing\u2019s syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia. Intern Med. 2011;50(21):2621\u20135.","journal-title":"Intern Med"},{"issue":"12","key":"2223_CR145","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2169\/internalmedicine.38.969","volume":"38","author":"M Nagai","year":"1999","unstructured":"Nagai M, Narita I, Omori K, Komura S, Arakawa M. Adrenocorticotropic hormone-independent bilateral adrenocortical macronodular hyperplasia treated with mitotane. Intern Med. 1999;38(12):969\u201373.","journal-title":"Intern Med"},{"issue":"12","key":"2223_CR146","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1210\/jc.2018-02638","volume":"104","author":"P Cohan","year":"2019","unstructured":"Cohan P, East HE, Galati SJ, Mercado JU, Lim PJ, Lamerson M, et al. Mifepristone treatment in four cases of primary bilateral macronodular adrenal hyperplasia (BMAH). J Clin Endocrinol Metab. 2019;104(12):6279\u201390.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2223_CR147","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.beem.2018.01.003","volume":"32","author":"M St-Jean","year":"2018","unstructured":"St-Jean M, Ghorayeb NE, Bourdeau I, Lacroix A. Aberrant G-protein coupled hormone receptor in adrenal diseases. Best Pract Res Clin Endocrinol Metab. 2018;32(2):165\u201387.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"7","key":"2223_CR148","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1507\/endocrj.K08E-370","volume":"56","author":"TL Mazzuco","year":"2009","unstructured":"Mazzuco TL, Chaffanjon P, Martinie M, Sturm N, Chabre O. Adrenal Cushing\u2019s syndrome due to bilateral macronodular adrenal hyperplasia: prediction of the efficacy of beta-blockade therapy and interest of unilateral adrenalectomy. Endocr J. 2009;56(7):867\u201377.","journal-title":"Endocr J"},{"issue":"9","key":"2223_CR149","first-page":"3168","volume":"81","author":"WW de Herder","year":"1996","unstructured":"de Herder WW, Hofland LJ, Usdin TB, de Jong FH, Uitterlinden P, van Koetsveld P, et al. Food-dependent Cushing\u2019s syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab. 1996;81(9):3168\u201372.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2223_CR150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1055\/s-0030-1270523","volume":"43","author":"V Preumont","year":"2011","unstructured":"Preumont V, Mermejo LM, Damoiseaux P, Lacroix A, Maiter D. Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing\u2019s syndrome. Horm Metab Res. 2011;43(4):287\u201391.","journal-title":"Horm Metab Res"},{"key":"2223_CR151","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00618","volume":"10","author":"S Larose","year":"2019","unstructured":"Larose S, Bondaz L, Mermejo LM, Latour M, Prosmanne O, Bourdeau I, et al. Coexistence of myelolipoma and primary bilateral macronodular adrenal hyperplasia with GIP-dependent Cushing\u2019s syndrome. Front Endocrinol (Lausanne). 2019;10:618.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"14","key":"2223_CR152","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJM199210013271403","volume":"327","author":"Y Reznik","year":"1992","unstructured":"Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, et al. Food-dependent Cushing\u2019s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med. 1992;327(14):981\u20136.","journal-title":"N Engl J Med"},{"key":"2223_CR153","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.peptides.2017.11.021","volume":"100","author":"LS Gasbjerg","year":"2018","unstructured":"Gasbjerg LS, Gabe MBN, Hartmann B, Christensen MB, Knop FK, Holst JJ, et al. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. Peptides. 2018;100:173\u201381.","journal-title":"Peptides"},{"issue":"2","key":"2223_CR154","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00125-017-4447-4","volume":"61","author":"LS Gasbjerg","year":"2018","unstructured":"Gasbjerg LS, Christensen MB, Hartmann B, Lanng AR, Sparre-Ulrich AH, Gabe MBN, et al. GIP(3\u201330)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. Diabetologia. 2018;61(2):413\u201323.","journal-title":"Diabetologia"},{"issue":"3","key":"2223_CR155","doi-asserted-by":"crossref","first-page":"R56","DOI":"10.1093\/ejendo\/lvad026","volume":"188","author":"A Lacroix","year":"2023","unstructured":"Lacroix A. Extensive expertise in endocrinology: glucose-dependent insulinotropic peptide-dependent Cushing\u2019s syndrome. Eur J Endocrinol. 2023;188(3):R56-72.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2223_CR156","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00063-002-1220-2","volume":"97","author":"M Im\u00f6hl","year":"2002","unstructured":"Im\u00f6hl M, K\u00f6ditz R, Stachon A, M\u00fcller KM, Nicolas V, Pfeilschifter J, et al. Katecholaminabh\u00e4ngiges heredit\u00e4res Cushing-Syndrom-Verlaufsbeobachtung nach einseitiger adrenalektomie [Catecholamine-dependent hereditary Cushing\u2019s syndrome - follow-up after unilateral adrenalectomy]. Med Klin (Munich). 2002;97(12):747\u201353.","journal-title":"Med Klin (Munich)"},{"issue":"9","key":"2223_CR157","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1590\/S0004-27302007000900007","volume":"51","author":"TL Mazzuco","year":"2007","unstructured":"Mazzuco TL, Thomas M, Martinie M, Cherradi N, Sturm N, Feige JJ, et al. Cellular and molecular abnormalities of a macronodular adrenal hyperplasia causing beta-blocker-sensitive Cushing\u2019s syndrome. Arq Bras Endocrinol Metabol. 2007;51(9):1452\u201362.","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"3","key":"2223_CR158","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12020-009-9246-3","volume":"36","author":"K Oki","year":"2009","unstructured":"Oki K, Yamane K, Nakanishi S, Nakashima R, Jitsuiki K, Kohno N. Improvement of hypercortisolism by \u03b2-blocker therapy in subclinical Cushing\u2019s syndrome associated with ACTH-independent macronodular adrenocortical hyperplasia. Endocrine. 2009;36(3):372\u20136.","journal-title":"Endocrine"},{"issue":"1","key":"2223_CR159","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/EJE-15-0642","volume":"174","author":"I Bourdeau","year":"2016","unstructured":"Bourdeau I, Oble S, Magne F, Levesque I, Caceres-Gorriti KY, Nolet S, et al. ARMC5 mutations in a large French-Canadian family with cortisol-secreting beta-adrenergic\/vasopressin responsive bilateral macronodular adrenal hyperplasia. Eur J Endocrinol. 2016;174(1):85\u201396.","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2223_CR160","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/cen.12763","volume":"82","author":"NM Albiger","year":"2015","unstructured":"Albiger NM, Ceccato F, Zilio M, Barbot M, Occhi G, Rizzati S, et al. An analysis of different therapeutic options in patients with Cushing\u2019s syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. Clin Endocrinol (Oxf). 2015;82(6):808\u201315.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"20","key":"2223_CR161","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM199711133372004","volume":"337","author":"A Lacroix","year":"1997","unstructured":"Lacroix A, Tremblay J, Rousseau G, Bouvier M, Hamet P. Propranolol therapy for ectopic beta-adrenergic receptors in adrenal Cushing\u2019s syndrome. N Engl J Med. 1997;337(20):1429\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"2223_CR162","doi-asserted-by":"crossref","first-page":"M45","DOI":"10.1530\/EJE-15-0200","volume":"173","author":"N El Ghorayeb","year":"2015","unstructured":"El Ghorayeb N, Bourdeau I, Lacroix A. Multiple aberrant hormone receptors in Cushing\u2019s syndrome. Eur J Endocrinol. 2015;173(4):M45-60.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2223_CR163","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1210\/clinem\/dgaa703","volume":"106","author":"M St-Jean","year":"2021","unstructured":"St-Jean M, Bourdeau I, Martin M, Lacroix A. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism. J Clin Endocrinol Metab. 2021;106(1):e45-60.","journal-title":"J Clin Endocrinol Metab"},{"issue":"21","key":"2223_CR164","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJM199911183412104","volume":"341","author":"A Lacroix","year":"1999","unstructured":"Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone\u2013dependent Cushing\u2019s syndrome. N Engl J Med. 1999;341(21):1577\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"2223_CR165","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1210\/jc.2002-021292","volume":"88","author":"MO Goodarzi","year":"2003","unstructured":"Goodarzi MO, Dawson DW, Li X, Lei Z, Shintaku P, Rao CV, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab. 2003;88(1):73\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2223_CR166","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.4158\/EP12346.CR","volume":"19","author":"O Karapanou","year":"2013","unstructured":"Karapanou O, Vlassopoulou B, Tzanela M, Stratigou T, Tsatlidis V, Tsirona S, et al. Adrenocorticotropic hormone independent macronodular adrenal hyperplasia due to aberrant receptor expression: is medical treatment always an option? Endocr Pract. 2013;19(3):e77-82.","journal-title":"Endocr Pract"},{"issue":"11","key":"2223_CR167","first-page":"456","volume":"62","author":"SA Bovenberg","year":"2004","unstructured":"Bovenberg SA, Pieters GF, Hofland LJ, Hermus AR. Leuprolide acetate therapy in LH-dependent Cushing\u2019s syndrome: in vivo and in vitro observations. Neth J Med. 2004;62(11):456\u20138.","journal-title":"Neth J Med"},{"issue":"11","key":"2223_CR168","first-page":"5534","volume":"86","author":"I Bourdeau","year":"2001","unstructured":"Bourdeau I, D\u2019Amour P, Hamet P, Boutin JM, Lacroix A. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2001;86(11):5534\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2223_CR169","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1055\/s-0043-122074","volume":"50","author":"F Hannah-Shmouni","year":"2018","unstructured":"Hannah-Shmouni F, Moraitis AG, Romero VV, Faucz FR, Mastroyannis SA, Berthon A, et al. Successful treatment of estrogen excess in primary bilateral macronodular adrenocortical hyperplasia with leuprolide acetate. Horm Metab Res. 2018;50(2):124\u201332.","journal-title":"Horm Metab Res"},{"issue":"4","key":"2223_CR170","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-19-0877","volume":"182","author":"J Young","year":"2020","unstructured":"Young J, Haissaguerre M, Viera-Pinto O, Chabre O, Baudin E, Tabarin A. MANAGEMENT OF ENDOCRINE DISEASE: Cushing\u2019s syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol. 2020;182(4):R29-58.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2223_CR171","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/clinem\/dgae258","volume":"109","author":"J Lavoillotte","year":"2024","unstructured":"Lavoillotte J, Mohammedi K, Salenave S, Furnica RM, Maiter D, Chanson P, et al. Personalized non-invasive diagnostic algorithms based on urinary free cortisol in ACTH-dependant Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2024;109(11):2882\u201391.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2223_CR172","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1530\/EJE-16-0809","volume":"176","author":"MV Davi","year":"2017","unstructured":"Davi MV, Cosaro E, Piacentini S, Reimondo G, Albiger N, Arnaldi G, et al. Prognostic factors in ectopic Cushing\u2019s syndrome due to neuroendocrine tumors: a multicenter study. Eur J Endocrinol. 2017;176(4):453\u201361.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2223_CR173","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1530\/EJE-15-0968","volume":"174","author":"K Kamp","year":"2016","unstructured":"Kamp K, Alwani RA, Korpershoek E, Franssen GJ, de Herder WW, Feelders RA. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors. Eur J Endocrinol. 2016;174(3):271\u201380.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2223_CR174","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1677\/JME-08-0110","volume":"42","author":"C De Bruin","year":"2009","unstructured":"De Bruin C, Feelders RA, Waaijers AM, Van Koetsveld PM, Sprij-Mooij DM, Lamberts SWJ, et al. Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. J Mol Endocrinol. 2009;42(1):47\u201356.","journal-title":"J Mol Endocrinol"},{"issue":"2","key":"2223_CR175","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jc.2011-1264","volume":"97","author":"C De Bruin","year":"2012","unstructured":"De Bruin C, Hofland LJ, Nieman LK, Van Koetsveld PM, Waaijers AM, Sprij-Mooij DM, et al. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing\u2019s syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab. 2012;97(2):455\u201362.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2223_CR176","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s12020-014-0391-y","volume":"49","author":"MV Davi\u2019","year":"2015","unstructured":"Davi\u2019 MV, Salgarello M, Francia G. Positive 68Ga-DOTATOC-PET\/CT after cortisol level control during ketoconazole treatment in a patient with liver metastases from a pancreatic neuroendocrine tumor and ectopic Cushing syndrome. Endocrine. 2015;49(2):566\u20137.","journal-title":"Endocrine"},{"issue":"4","key":"2223_CR177","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","volume":"35","author":"N Sonino","year":"1991","unstructured":"Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing\u2019s syndrome: experience in 34 patients. Clin Endocrinol (Oxf). 1991;35(4):347\u201352.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2223_CR178","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2265.1991.tb01737.x","volume":"34","author":"A Tabarin","year":"1991","unstructured":"Tabarin A, Navarranne A, Guerin J, Corcuff JB, Parneix M, Roger P. Use of ketoconazole in the treatment of Cushing\u2019s disease and ectopic ACTH syndrome. Clin Endocrinol (Oxf). 1991;34(1):63\u20139.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2223_CR179","doi-asserted-by":"crossref","first-page":"L1","DOI":"10.1530\/EJE-18-0694","volume":"179","author":"M Ollivier","year":"2018","unstructured":"Ollivier M, Haissaguerre M, Ferriere A, Tabarin A. Should we avoid using ketoconazole in patients with severe Cushing\u2019s syndrome and increased levels of liver enzymes? Eur J Endocrinol. 2018;179(5):L1-2.","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2223_CR180","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1507\/endocrj.K10E-265","volume":"57","author":"M Doi","year":"2010","unstructured":"Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J. 2010;57(12):1061\u20139.","journal-title":"Endocr J"},{"issue":"6","key":"2223_CR181","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1301428","volume":"369","author":"C Baudry","year":"2013","unstructured":"Baudry C, Paepegaey AC, Groussin L. Reversal of Cushing\u2019s syndrome by vandetanib in medullary thyroid carcinoma. N Engl J Med. 2013;369(6):584\u20136.","journal-title":"N Engl J Med"},{"issue":"1","key":"2223_CR182","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s12020-014-0352-5","volume":"49","author":"P Marques","year":"2015","unstructured":"Marques P, Da Silva Vieira M, Bugalho MJ. Ectopic Cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with sunitinib. Endocrine. 2015;49(1):290\u20132.","journal-title":"Endocrine"},{"key":"2223_CR183","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvae163.2060","author":"E Davydov","year":"2024","unstructured":"Davydov E, Severson D, Athimulam S. 7713 remission of ectopic Cushing syndrome due to medullary thyroid cancer with selpercatinib. J Endocr Soc. 2024. https:\/\/doi.org\/10.1210\/jendso\/bvae163.2060.","journal-title":"J Endocr Soc"},{"key":"2223_CR184","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad174","author":"A Jazdarehee","year":"2024","unstructured":"Jazdarehee A, Abdel-Rahman O, Jacquier JE. Remission of ectopic Cushing syndrome secondary to medullary thyroid cancer with vandetanib and selpercatinib. JCEM Case Reports. 2024. https:\/\/doi.org\/10.1210\/jcemcr\/luad174.","journal-title":"JCEM Case Reports"},{"issue":"4","key":"2223_CR185","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsmedchemlett.3c00514","volume":"15","author":"SH Kim","year":"2024","unstructured":"Kim SH, Han S, Zhao J, Wang S, Kusnetzow AK, Reinhart G, et al. Discovery of CRN04894: a novel potent selective MC2R antagonist. ACS Med Chem Lett. 2024;15(4):478\u201385.","journal-title":"ACS Med Chem Lett"},{"issue":"Suppl 1","key":"2223_CR186","doi-asserted-by":"crossref","first-page":"A167","DOI":"10.1210\/jendso\/bvab048.337","volume":"5","author":"MA Fowler","year":"2021","unstructured":"Fowler MA, Kusnetzow AK, Han S, Reinhardt G, Kim SH, Johns M, et al. Effects of CRN04894, a nonpeptide orally bioavailable ACTH antagonist, on corticosterone in rodent models of ACTH excess. J Endocr Soc. 2021;5(Suppl 1):A167.","journal-title":"J Endocr Soc."},{"issue":"Suppl 1","key":"2223_CR187","first-page":"A61","volume":"8","author":"H Elenius","year":"2024","unstructured":"Elenius H, McGlotten R, Moore C, Omotosho YB, Ayala A, Wu Y, et al. Atumelnant (crn04894) induces rapid and sustained reductions in serum and urine cortisol in patients with ACTH-dependent Cushing syndrome during a phase 1b\/2a, single center, 10-day, inpatient, open-label study. J Endocr Soc. 2024;8(Suppl 1):A61\u20132.","journal-title":"J Endocr Soc."},{"issue":"Suppl 1","key":"2223_CR188","first-page":"A133","volume":"8","author":"RA Auchus","year":"2024","unstructured":"Auchus RA, Trainer PJ, Lucas KJ, Bruera D, Marko J, Ayala A, et al. Once daily oral atumelnant (CRN04894) induces rapid and profound reductions of androstenedione and 17-hydroxyprogesterone in participants with classical congenital adrenal hyperplasia: initial results from a 12-week, phase 2, open-label study. J Endocr Soc. 2024;8(Suppl 1):A133\u20134.","journal-title":"J Endocr Soc"},{"issue":"1","key":"2223_CR189","first-page":"1","volume":"158","author":"AL Feldhaus","year":"2017","unstructured":"Feldhaus AL, Anderson K, Dutzar B, Ojala E, McNeill PD, Fan P, et al. ALD1613, a novel long-acting monoclonal antibody to control ACTH-driven pharmacology. Endocrinology. 2017;158(1):1\u20138.","journal-title":"Endocrinology"},{"issue":"7","key":"2223_CR190","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1210\/en.2019-00117","volume":"160","author":"AL Gehrand","year":"2019","unstructured":"Gehrand AL, Phillips J, Malott K, Raff H. A long-acting neutralizing monoclonal ACTH antibody blocks corticosterone and adrenal gene responses in neonatal rats. Endocrinology. 2019;160(7):1719\u201330.","journal-title":"Endocrinology"},{"issue":"3","key":"2223_CR191","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","volume":"25","author":"ZY Ma","year":"2015","unstructured":"Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, Zhou LF, et al. Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease. Cell Res. 2015;25(3):306\u201317.","journal-title":"Cell Res"},{"issue":"7","key":"2223_CR192","doi-asserted-by":"crossref","first-page":"E997","DOI":"10.1210\/jc.2015-1453","volume":"100","author":"LG Perez-Rivas","year":"2015","unstructured":"Perez-Rivas LG, Theodoropoulou M, Ferrau F, Nusser C, Kawaguchi K, Stratakis CA, et al. The gene of the ubiquitin-specific protease 8 Is frequently mutated in adenomas causing Cushing\u2019s disease. J Clin Endocrinol Metab. 2015;100(7):E997-1004.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2223_CR193","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","volume":"47","author":"M Reincke","year":"2015","unstructured":"Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease. Nat Genet. 2015;47(1):31\u20138.","journal-title":"Nat Genet"},{"issue":"12","key":"2223_CR194","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","volume":"121","author":"H Fukuoka","year":"2011","unstructured":"Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Investig. 2011;121(12):4712\u201321.","journal-title":"J Clin Investig"},{"issue":"8","key":"2223_CR195","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1530\/ERC-21-0093","volume":"28","author":"D Treppiedi","year":"2021","unstructured":"Treppiedi D, Di Muro G, Marra G, Barbieri AM, Mangili F, Catalano R, et al. USP8 inhibitor RA-9 reduces ACTH release and cell growth in tumor corticotrophs. Endocr Relat Cancer. 2021;28(8):573\u201382.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2223_CR196","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1507\/endocrj.EJ19-0239","volume":"67","author":"K Kageyama","year":"2020","unstructured":"Kageyama K, Asari Y, Sugimoto Y, Niioka K, Daimon M. Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation. Endocr J. 2020;67(2):177\u201384.","journal-title":"Endocr J"},{"issue":"6","key":"2223_CR197","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1507\/endocrj.EJ18-0491","volume":"66","author":"Y Asari","year":"2019","unstructured":"Asari Y, Kageyama K, Sugiyama A, Kogawa H, Niioka K, Daimon M. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells. Endocr J. 2019;66(6):515\u201322.","journal-title":"Endocr J"},{"issue":"8","key":"2223_CR198","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/ERC-22-0088","volume":"29","author":"A Albani","year":"2022","unstructured":"Albani A, Perez-Rivas LG, Tang S, Simon J, Lucia KE, Colon-Bolea P, et al. Improved pasireotide response in USP8 mutant corticotroph tumours in vitro. Endocr Relat Cancer. 2022;29(8):503\u201311.","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2223_CR199","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102455","volume":"14","author":"D Treppiedi","year":"2022","unstructured":"Treppiedi D, Marra G, Di Muro G, Esposito E, Barbieri AM, Catalano R, et al. P720R USP8 mutation is associated with a better responsiveness to pasireotide in ACTH-secreting PitNETs. Cancers (Basel). 2022;14(10):2455.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2223_CR200","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1530\/EC-20-0035","volume":"9","author":"S Castellnou","year":"2020","unstructured":"Castellnou S, Vasiljevic A, Lapras V, Raverot V, Alix E, Borson-Chazot F, et al. SST5 expression and USP8 mutation in functioning and silent corticotroph pituitary tumors. Endocr Connect. 2020;9(3):243\u201353.","journal-title":"Endocr Connect"},{"issue":"1","key":"2223_CR201","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/eje.0.143r001","volume":"143","author":"S Jordan","year":"2000","unstructured":"Jordan S, Lidhar K, Korbonits M, Lowe DG, Grossman AB. Cyclin d and cyclin e expression in normal and adenomatous pituitary. Eur J Endocrinol. 2000;143(1):R1-6.","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2223_CR202","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1210\/jc.2015-1606","volume":"100","author":"NA Liu","year":"2015","unstructured":"Liu NA, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y, et al. Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease. J Clin Endocrinol Metab. 2015;100(7):2557\u201364.","journal-title":"J Clin Endocrinol Metab"},{"issue":"20","key":"2223_CR203","doi-asserted-by":"crossref","first-page":"8414","DOI":"10.1073\/pnas.1018091108","volume":"108","author":"NA Liu","year":"2011","unstructured":"Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, et al. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A. 2011;108(20):8414\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2223_CR204","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/clinem\/dgac588","volume":"108","author":"NA Liu","year":"2023","unstructured":"Liu NA, Ben-Shlomo A, Carmichael JD, Wang C, Swerdloff RS, Heaney AP, et al. Treatment of Cushing disease with pituitary-targeting seliciclib. J Clin Endocrinol Metab. 2023;108(3):726\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2223_CR205","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126469","volume":"23","author":"D Regazzo","year":"2022","unstructured":"Regazzo D, Mondin A, Scaroni C, Occhi G, Barbot M. The role of glucocorticoid receptor in the pathophysiology of pituitary corticotroph adenomas. Int J Mol Sci. 2022;23(12):6469.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2223_CR206","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nm.3776","volume":"21","author":"M Riebold","year":"2015","unstructured":"Riebold M, Kozany C, Freiburger L, Sattler M, Buchfelder M, Hausch F, et al. A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease. Nat Med. 2015;21(3):276\u201380.","journal-title":"Nat Med"},{"issue":"4","key":"2223_CR207","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s11102-014-0607-4","volume":"18","author":"A Sugiyama","year":"2015","unstructured":"Sugiyama A, Kageyama K, Murasawa S, Ishigame N, Niioka K, Daimon M. Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells. Pituitary. 2015;18(4):542\u201353.","journal-title":"Pituitary"},{"issue":"6","key":"2223_CR208","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000529710","volume":"113","author":"F Pecori Giraldi","year":"2023","unstructured":"Pecori Giraldi F, Cassarino MF, Sesta A, Lasio G, Losa M. Silibinin, an HSP90 inhibitor, on human ACTH-secreting adenomas. Neuroendocrinology. 2023;113(6):606\u201314.","journal-title":"Neuroendocrinology"},{"key":"2223_CR209","volume":"15","author":"PP Ray","year":"2024","unstructured":"Ray PP, Islam MA, Islam MS, Han A, Geng P, Aziz MA, et al. A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment. Front Pharmacol. 2024;15:1349745.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2223_CR210","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-025-10253-7","volume":"44","author":"A Suraweera","year":"2025","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Epigenetic drugs in cancer therapy. Cancer Metastasis Rev. 2025;44(1):37.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"2223_CR211","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1210\/clinem\/dgaa699","volume":"106","author":"D Zhang","year":"2021","unstructured":"Zhang D, Damoiseaux R, Babayan L, Rivera-Meza EK, Yang Y, Bergsneider M, et al. Targeting corticotroph HDAC and PI3-kinase in Cushing disease. J Clin Endocrinol Metab. 2021;106(1):e232\u201346.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2223_CR212","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/en.2006-0414","volume":"147","author":"V Castillo","year":"2006","unstructured":"Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, et al. Retinoic acid as a novel medical therapy for Cushing\u2019s disease in dogs. Endocrinology. 2006;147(9):4438\u201344.","journal-title":"Endocrinology"},{"issue":"8","key":"2223_CR213","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1172\/JCI11098","volume":"108","author":"M Paez-Pereda","year":"2001","unstructured":"Paez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Investig. 2001;108(8):1123\u201331.","journal-title":"J Clin Investig"},{"issue":"9","key":"2223_CR214","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1210\/en.2013-1820","volume":"155","author":"G Occhi","year":"2014","unstructured":"Occhi G, Regazzo D, Albiger NM, Ceccato F, Ferasin S, Scanarini M, et al. Activation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing\u2019s disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiation. Endocrinology. 2014;155(9):3538\u201349.","journal-title":"Endocrinology"},{"issue":"10","key":"2223_CR215","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1210\/jc.2012-2328","volume":"97","author":"F Pecori Giraldi","year":"2012","unstructured":"Pecori Giraldi F, Ambrogio AG, Andrioli M, Sanguin F, Karamouzis I, Corsello SM, et al. Potential role for retinoic acid in patients with Cushing\u2019s disease. J Clin Endocrinol Metab. 2012;97(10):3577\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"2223_CR216","doi-asserted-by":"crossref","first-page":"8173182","DOI":"10.1155\/2016\/8173182","volume":"2016","author":"L Vilar","year":"2016","unstructured":"Vilar L, Albuquerque JL, Lyra R, Trovao Diniz E, Rangel Filho F, Gadelha P, et al. The role of isotretinoin therapy for Cushing\u2019s disease: results of a prospective study. Int J Endocrinol. 2016;2016:8173182.","journal-title":"Int J Endocrinol."},{"key":"2223_CR217","unstructured":"Signifor (pasireotide diaspartate) [package insert]. Bridgewater, NJ: Recordati Rare Diseases; 2024."},{"key":"2223_CR218","unstructured":"Signifor LAR (pasireotide pamoate) [package insert]. Bridgewater, NJ: Recordati Rare Diseases; 2024."},{"key":"2223_CR219","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.732240","volume":"12","author":"J Sim\u00f5es Corr\u00eaa Galendi","year":"2021","unstructured":"Sim\u00f5es Corr\u00eaa Galendi J, Correa Neto ANS, Demetres M, Boguszewski CL, Nogueira VDSN. Effectiveness of medical treatment of Cushing\u2019s disease: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:732240.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02223-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02223-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02223-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T02:09:19Z","timestamp":1759284559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02223-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":219,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2223"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02223-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,15]]},"assertion":[{"value":"30 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to assist with the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nidhi Agrawal is on the advisory board for Xeris, Amryt, Camurus, Crinetics, and Novo Nordisk and serves as a principal investigator on research trials for Amryt, Recordati, Ascendis, and Novo Nordisk. Antoine Tabarin has received speaker and board honoraria from Recordati and HRA Pharma. Andr\u00e9 Lacroix has received research grants and speaker fees from Pfizer Canada and Recordati Canada Rare Diseases, speaker fees from Medunik Canada, and royalties as an editor of the adrenal section of UpToDate and Encyclopedia of Endocrine Diseases and is a co-inventor on a patent for endocrine diseases related to\n                      KDM1A\n                      for work registered at the Universite Paris\u2013Saclay. Richard A. Feelders has received speaker fees and research grants from Recordati and Corcept. Brendan R. Dillon, Yair Schwarz, Kristen Dancel-Manning, and Leo J. Hofland have no interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Brendan R. Dillon, Nidhi Agrawal, Yair Schwarz, Antoine Tabarin, Andr\u00e9 Lacroix, Leo J. Hofland, and Richard A. Feelders contributed to manuscript conceptualization, literature search, original draft preparation, and review and editing. Kristen Dancel-Manning created the figures using Adobe Illustrator, Adobe Fresco, and Microsoft PowerPoint. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}